The Grainger group has focused on innovative delivery methods and biotechnology-based drugs. These include:
1. local delivery of therapeutic antibodies to prevent infection
2. local delivery of siRNA targeting molecular mediators of osteoporosis and fibrosis
3. silver nanoparticle "first in human" oral and ocular toxicity studies
4. dendrimer-blood interactions and pro-coagulant activity in vitro and in vivo
5. ballistic delivery of live vaccines to address animal health issues
6. sensor-based delivery of TKI small molecule drugs to address foreign body response
7. three-dimensional in vitro cell-based culture models for drug toxicity screening.